retatrutide clinical trials obesity ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial retatrutide clinical trial obesity Eli

"Press Release: Palatin Technologies Announces Litigation Settlement With Competitive Technologies"

GLP-1 users showed a 49% higher risk for vitamin D deficiency compared to people on SGLT2 inhibitors and a 32% higher risk compared to those on DPP-4 inhibitors

Protocols, doses, and reactions reported below come from small published clinical trials and self-reported community sources

Using biologics such as enzymes, manufacturers may be able to assemble peptide chains in a water-based environmentan approach that could unlock multiple benefits: Less dependence on hazardous chemicals: By shifting away from a chemical-heavy solid-phase synthesis approach, manufacturers could free themselves from the costs and complexities of sourcing, storing, handling, and disposing of hazardous raw materials

Participants reported their own characteristics, including age, sex and weight at baseline